In November 2009, Romidepsin (Istodax®), a second HDAC inhibitor, was approved by the FDA for CTCL, with an overall response rate of 34%, and it was later approved for peripheral T-cell lymphoma (PTCL) [6]. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.